Latest in: drug development
Featured Image

A Freedom-To-Operate analysis – do you need to bother?

When a company is in the process of strategizing the development and release of a new product, a notable concern arises, especially in technology-driven fields abundant with patents. The risk is the potential impedance …
gravatar
 · 
August 11, 2023
Featured Image

Top 3 news from ASCO 2023

American Society of Clinical Oncology (ASCO) Annual Meeting was held between the 2nd and 6th June in Chcago, USA. As the last year, here we look at the top 3 highlights we take from …
gravatar
 · 
June 13, 2023
Featured Image

Life science incentives; UAE vs Central Europe

UAE has become one of the leading Middle Eastern countries in the biotechnology and pharmaceutical industry due to its heavy investment and development in the sector. In particular, the Dubai Free Zones and the …
gravatar
 · 
March 16, 2023
Featured Image

7.9% of drugs entering clinical development were approved by FDA over the past decade.

Clinical research success rates of different disease areas have far-reaching implications in the structure of corporate R&D budgets, pharmaceutical asset valuation and, eventually, M&A activity. The report published in February 2021 considers success rates of clinical …
gravatar
 · 
July 5, 2022

Impressum

ambiom s.r.o.
Karpatské námestie 7770/10A
831 06 Bratislava
IČO: 54219035

Contact

info@ambiom.com
+421 948 652 276

footer-FB
footer-Li
Footer-Insta

Newsletter

Back to top Arrow